OncoMatch/Clinical Trials/NCT06827899
Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML
Is NCT06827899 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) for acute myeloid leukemia.
Treatment: veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) — A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: BCR ABL1 translocation
AML with BCR-ABL1 translocation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: hypomethylation agent
Participants have received the following treatments: hypomethylation agents
Cannot have received: BCL2 inhibitor (venetoclax)
Participants have received the following treatments: venetoclax
Cannot have received: chemotherapy for myelodysplastic syndrome (MDS)
Participants have received the following treatments: chemotherapy for myelodysplastic syndrome (MDS)
Lab requirements
Kidney function
Estimated creatinine clearance >= 30 mL/min
Liver function
AST and ALT <= 3.0 x ULN (unless considered due to leukemic organ involvement). Bilirubin <= 1.5 x ULN (unless considered due to leukemic organ involvement)
Cardiac function
Clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia and atrial fibrillation, second-degree heart block, myocardial infarction, and congestive heart failure within one year before enrollment patients, and patients with coronary heart disease who have clinical symptoms and need drug treatment [excluded]
AST and ALT <= 3.0 x ULN (unless considered due to leukemic organ involvement). Bilirubin <= 1.5 x ULN (unless considered due to leukemic organ involvement); Estimated creatinine clearance >= 30 mL/min; Clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia and atrial fibrillation, second-degree heart block, myocardial infarction, and congestive heart failure within one year before enrollment patients, and patients with coronary heart disease who have clinical symptoms and need drug treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06827899 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with BCR alterations eligible?
No. BCR ABL1 translocation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages